OBJECTIVES: Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general population. The main aim of this study is to estimate the numbers of users of substances with psychedelic properties (classical psychedelics, cannabis, ecstasy, and ketamine) in the Czech Republic. METHODS: Data from two samples enrolled in representative cross-sectional questionnaire surveys in the Czech adult population in 2016 (n = 2,785) and 2018 (n = 1,665) were analysed. Prevalence rates were extrapolated to estimate numbers of current, i.e., last-year, users of psychedelics, and their socio-demographic profiles were compared with non-users and users of cannabis. RESULTS: An estimated 5-6% of the Czech adult population (350-430 thousand people) used classical psychedelics (LSD, psilocybin mushrooms, ayahuasca) in their lifetime, increasing up to 28-30% when cannabis is included (1.9-2.1 million users). Current use of classical psychedelics reached 0.7-1.9% (50-130 thousand people), and 9-11% (590-750 thousand users) when cannabis was included. Users of psychedelics were more often males, of younger age and single. CONCLUSIONS: No significant socio-demographic differences were found between users of classical psychedelics and recreational cannabis users, however, differences were significant when compared to non-users and users of other illicit drugs. Findings should further serve to inform drug policy and social and healthcare systems in respect to the use of psychedelics.

Beyond Psychedelics Prague Czech Republic

Czech National Monitoring Centre for Drugs and Addiction Office of the Government of the Czech Republic Prague Czech Republic

Department of Addictology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Faculty of Arts Charles University Prague Czech Republic

Faculty of Pharmacy Masaryk University Brno Czech Republic

National Institute of Mental Health Klecany Czech Republic

Spolecnost Podane ruce Brno Czech Republic

Zobrazit více v PubMed

Guerra-Doce E. Psychoactive substances in prehistoric times: examining the archaeological evidence. Time Mind. 2015;8(1):91-112.

Schultes RE. Hallucinogens of plant origin. Science. 1969;163(3864):245-54.

Hofmann A, Rätsch C. Plants of the gods: their sacred, healing, and hallucinogenic powers. Rochester, Vermont: Healing Arts Press; 2001.

Akers BP, Ruiz JF, Piper A, Ruck CA. A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Economic Botany. 2011;65(2):121-8.

Miller MJ, Albarracin-Jordan J, Moore C, Capriles JM. Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proc Natl Acad Sci U S A. 2019;116(23):11207-12. PubMed

Hazekamp A, Pappas G. Self-medication with cannabis. In: Pertwee RG, editor. Handbook of Cannabis. New York: Oxford University Press; 2014. p. 319-38.

Mason NL, Kuypers KP. Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics. J Psychedelic Stud. 2018;2(1):45-52.

Harris R, Gurel L. A study of ayahuasca use in North America. J Psychoactive Drugs. 2012;44(3):209-15.

Kavenská V, Vosáhlová Š. Experience with ayahuasca in Europe - motives, possible benefits and risks. E-psychologie. 2013;4(7):28-39. (In Czech.)

Móró L, Simon K, Bárd I, Rácz J. Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs. 2011;43(3):188-98.

Bláhová B, Horák M, Verter N. Self-medication with cannabis in the Czech Republic from an anthropological perspective. Anthropologia Integra. 2017;8(2):77-87.

Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355. PubMed

Gallimore AR. Restructuring consciousness - the psychedelic state in light of integrated information theory. Front Hum Neurosci. 2015;9:346. doi: 10.3389/fnhum.2015.00346. PubMed DOI

Freedman DX. The psychopharmacology of hallucinogenic agents. Annu Rev Med. 1969;20:409-18.

Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32(7):811-9. PubMed

Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponté KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166.

MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453-61. PubMed

Dos Santos RG, Osório FL, Crippa JAS, Riba J, Zuardi AW, Hallak JEC. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6(3):193-213.

Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, von Heyden M, Aicher H, et al. Positive psychology in the investigation of psychedelics and entactogens: a critical review. Neuropharmacology. 2018;142:179-99. PubMed

Bahji A, Forsyth A, Groll D, Hawken ER. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA) - assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109735. doi: 10.1016/j.pnpbp.2019.109735. PubMed DOI

Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101(2):209-19.

Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42(3):180-8.

Carhart-Harris RL, Nutt D. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Substance Use. 2010;15(4):283-300.

Krebs TS, Johansen PO. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972. doi: 10.1371/journal.pone.0063972. PubMed DOI

Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270-9. PubMed

Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280-8. PubMed

Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558-65.

Coomber R. Assessing the real dangers of illicit drugs - risk analysis as the way forward? Addict Res. 1999;7(2):85-90.

Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-20. PubMed

European Monitoring Centre for Drugs and Drug Addiction. Handbook for surveys on drug use among the general population: EMCDDA project CT.99.EP.08 B. Lisbon: EMCDDA; 2002.

Chomynová P, Mravčík V. National survey on substance use 2016. Zaostřeno. 2018;4(2):1-20. (In Czech.)

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Černíková T, Rous Z, et al. Annual report on drug situation in the Czech Republic in 2018. Prague: Government of the Czech Republic; 2019. (In Czech.)

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020: trends and developments. Luxembourg: Publications Office of the European Union; 2020.

Mravčík V, Chomynová P, Grohmannová K, Janíková B, Černíková T, Rous Z, et al. Annual report on drug situation in the Czech Republic in 2019. Prague: Government of the Czech Republic; 2020. (In Czech.)

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: trends and developments. Luxembourg: Publications Office of the European Union; 2019.

Chomynová P, Csémy L, Mravčík V. European School Survey Project on Alcohol and Other Drugs (ESPAD) 2019. Zaostřeno. 2020;6(5):1-20. (In Czech.)

ESPAD Group. ESPAD Report 2019: results from the European School Survey on Alcohol and Other Drugs. Luxembourg: Publications Office of the European Union; 2020.

Zuckerman M, Neeb M. Demographic influences in sensation seeking and expressions of sensation seeking in religion, smoking and driving habits. Pers Individ Diff. 1980;1(3):197-206.

Martin CA, Kelly TH, Rayens MK, Brogli BR, Brenzel A, Smith WJ, et al. Sensation seeking, puberty, and nicotine, alcohol, and marijuana use in adolescence. J Am Acad Child Adolesc Psychiatry. 2002;41(12):1495-502.

Donohew RL, Hoyle RH, Clayton RR, Skinner WF, Colon SE, Rice RE. Sensation seeking and drug use by adolescents and their friends: models for marijuana and alcohol. J Stud Alcohol. 1999;60(5):622-31. PubMed

Crawford AM, Pentz MA, Chou C-P, Li C, Dwyer JH. Parallel developmental trajectories of sensation seeking and regular substance use in adolescents. Psychol Addict Behav. 2003;17(3):179-92.

Hittner JB, Swickert R. Sensation seeking and alcohol use: a meta-analytic review. Addict Behav. 2006;31(8):1383-401. PubMed

Zuckerman M. Sensation seeking and risky behavior. Washington, DC: American Psychological Association; 2007.

Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007;20(4):359-64. PubMed

Thomsen PH. Schizophrenia with childhood and adolescent onset - a nationwide register-based study. Acta Psychiatr Scand. 1996;94(3):187-93. PubMed

Vogels N, Brunt TM, Rigter S, Van Dijk P, Vervaeke H, Niesink RJM. Content of ecstasy in the Netherlands: 1993-2008. Addiction. 2009;104(12):2057-66.

Palamar JJ. There's something about Molly: the underresearched yet popular powder form of ecstasy in the United States. Subs Abus. 2017;38(1):15-7.

van der Gouwe D, Brunt TM, van Laar M, van der Pol P. Purity, adulteration and price of drugs bought on-line versus off-line in the Netherlands. Addiction. 2017;112(4):640-8.